Alkermes Plc (ALKS)

20.12
0.17 0.85
NASDAQ : Health Technology
Prev Close 19.95
Open 19.88
Day Low/High 19.88 / 20.38
52 Wk Low/High 17.11 / 37.75
Volume 2.67M
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 157.52M
Market Cap 3.18B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes' Corporate Presentation To Be Webcast At Upcoming Healthcare Conferences

Alkermes' Corporate Presentation To Be Webcast At Upcoming Healthcare Conferences

DUBLIN, Nov. 12, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, Nov.

Alkermes Announces Receipt Of $150 Million Milestone Payment From Biogen Related To FDA Approval Of VUMERITY™

Alkermes Announces Receipt Of $150 Million Milestone Payment From Biogen Related To FDA Approval Of VUMERITY™

DUBLIN, Nov. 12, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.

Alkermes Announces New Data From ALKS 4230 Clinical Development Program At Society For Immunotherapy Of Cancer's (SITC) 34th Annual Meeting

Alkermes Announces New Data From ALKS 4230 Clinical Development Program At Society For Immunotherapy Of Cancer's (SITC) 34th Annual Meeting

̶ Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab ̶

Alkermes To Present Data From ALKS 4230 Clinical Development Program At The Society For Immunotherapy Of Cancer's (SITC) 34th Annual Meeting

Alkermes To Present Data From ALKS 4230 Clinical Development Program At The Society For Immunotherapy Of Cancer's (SITC) 34th Annual Meeting

- Supplemental Materials Will be Made Available on Alkermes' Website on Friday, Nov. 8 -

Biogen And Alkermes Announce FDA Approval Of VUMERITY™ (diroximel Fumarate) For Multiple Sclerosis

Biogen And Alkermes Announce FDA Approval Of VUMERITY™ (diroximel Fumarate) For Multiple Sclerosis

- VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability -

Alkermes Plc Reports Third Quarter 2019 Financial Results And Implementation Of Restructuring

Alkermes Plc Reports Third Quarter 2019 Financial Results And Implementation Of Restructuring

-- Third Quarter Revenues of $255.2 Million, Primarily Driven by Approximately 20% Year-Over-Year Growth of Proprietary Product Net Sales --

First Week Of December 20th Options Trading For Alkermes (ALKS)

First Week Of December 20th Options Trading For Alkermes (ALKS)

Investors in Alkermes plc saw new options become available this week, for the December 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALKS options chain for the new December 20th contracts and identified one put and one call contract of particular interest.

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center For Novel Immuno-Oncology Drug Candidate ALKS 4230

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center For Novel Immuno-Oncology Drug Candidate ALKS 4230

-- Planned Phase 2 Multi-Site Trial to Evaluate ALKS 4230 in Combination With Pembrolizumab in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer --

Alkermes To Host Conference Call To Discuss Third Quarter 2019 Financial Results

Alkermes To Host Conference Call To Discuss Third Quarter 2019 Financial Results

DUBLIN, Oct. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.

Alkermes Presents New Health Economics And Outcomes Research On Patients With Schizophrenia And Bipolar I Disorder At 2019 Psych Congress

Alkermes Presents New Health Economics And Outcomes Research On Patients With Schizophrenia And Bipolar I Disorder At 2019 Psych Congress

-- Findings From Patient Surveys Underscore Need for New Antipsychotic Treatments With Reduced Side Effects --

Alkermes To Present At The Cantor Fitzgerald Global Healthcare Conference

Alkermes To Present At The Cantor Fitzgerald Global Healthcare Conference

DUBLIN, Sept. 26, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct.

Alkermes Announces The Appointment Of Richard Gaynor, M.D. And Andy Wilson To Its Board Of Directors And The Retirement Of Director Floyd Bloom, M.D.

Alkermes Announces The Appointment Of Richard Gaynor, M.D. And Andy Wilson To Its Board Of Directors And The Retirement Of Director Floyd Bloom, M.D.

DUBLIN, Sept. 13, 2019 /PRNewswire/ --   Alkermes plc (Nasdaq: ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

-- Patent Trial and Appeal Board Oral Hearing Cancelled --

Alkermes Plc Reports Second Quarter 2019 Financial Results

Alkermes Plc Reports Second Quarter 2019 Financial Results

-- Second Quarter Revenues of $279.9 Million, Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes To Host Conference Call To Discuss Second Quarter 2019 Financial Results

Alkermes To Host Conference Call To Discuss Second Quarter 2019 Financial Results

DUBLIN, July 18, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.

Alkermes Expands Planned New Drug Application For ALKS 3831 To Include Treatment Of Bipolar I Disorder

Alkermes Expands Planned New Drug Application For ALKS 3831 To Include Treatment Of Bipolar I Disorder

-- Following Pre-NDA Meeting With FDA, Company Plans to Submit New Drug Application for Schizophrenia and Bipolar I Disorder Indications in the Fourth Quarter of 2019 --

Alkermes Demonstrates Commitment To Local Community For 11th Consecutive Year With Largest Volunteer Event In Company History

Alkermes Demonstrates Commitment To Local Community For 11th Consecutive Year With Largest Volunteer Event In Company History

WALTHAM, Mass., July 1, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that for the 11 th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater...

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage --

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FWONA, FWONK, HMN Downgrades: AAME, ABEV, ABR, ALKS, CCS, EXP, PKE, PTR, SCSC, SILC, SMLP, SNMP, TR, TSE Initiations: LAZY, VXRT Read on to get TheStreet Quant Ratings' detailed report:

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ALKS, AUY, BY, CCS, CXO, DVN, HGV, IESC, KRG, OMF, VRNT Downgrades: ARR, CTG, JAZZ, PTN, ROX Initiations: LBRT, NINE Read on to get TheStreet Quant Ratings' detailed report:

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Law Offices of Howard G. Smith reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the...

TheStreet Quant Rating: D (Sell)